GLPwatch
Mounjaro for Anxiety
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for anxiety, and any use for this condition is off-label or investigational. The listed research reports psychiatric adverse events and suicidal ideation associated with tirzepatide but does not establish a direct link to anxiety.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Anxiety |
| Approval status | Investigational / off-label |
| Research papers | 3 |
Mounjaro is not FDA-approved for anxiety; the research below reflects investigational or off-label study only.
Research on tirzepatide for anxiety (3)
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.